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in functioning is considered pathological if it lasts at least 
half a day for two weeks10. Most studies have assessed 
prevalence of Anxiety Disorders in cancer patients to be 
between 15–28%1,11. There is a problem in diagnosing 
Anxiety Disorders in physically ill people12,13. The current 
DSM-IV classifi cation of Anxiety and Depressive Disor-
ders is based on physical symptoms which are not relevant 
in diagnosis of those disorders in somatic patients14,15. In 
cancer patients anxiety is accompanied with stronger re-
actions of autonomic nervous system then is the case in 
patients with chronic anxiety (i.e. Generalized Anxiety 
Disorder). Additionally, anxious and depressive symptoms 
usually present themselves together with an overlap1.
Although treatment of breast cancer has signifi cantly 
advanced in recent years, diagnosis and treatment of can-
cer still causes much distress1–3. Affected women must face 
with future uncertainties, sometimes with very serious 
treatment side effects, the feeling of isolation, stigma and 
feeling of guilt, physical dysfunction and changes in body 
image4–8. Therapeutic approaches often additionally rein-
force anxiety which then interferes with the treatment 
tolerance and the treatment procedure making patients 
more ambivalent towards therapy.
Even though anxiety is a normal reaction to stress, 
some people display more pronounced reactions and symp-
toms that overwhelm them and disrupt their everyday 
functioning9. Enduring anxiety that induces diffi culties 
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A B S T R A C T
Being diagnosed with breast cancer is a traumatic event that can lead to development of different mental disorders and 
infl uences all aspects of affected woman’s life. Anxiety and Depressive Disorders in physically ill people still don’t have clear 
diagnostic criteria which make diagnosis and treatment very diffi cult since different psychiatric therapeutic approaches 
have different effects. The aim was to evaluate infl uence of separate and combined psychotherapeutic approach (psychody-
namic and cognitive-behavioral) and psychopharmacotherapy on decrease of anxiety and depression in breast cancer pa-
tients. The sample consisted of 120 subjects divided into four groups. The fi rst group of patients was treated with psycho-
pharmacotherapy, the second group received psychotherapy, the third group was treated with the combination of 
psychopharmacotherapy and psychotherapy, and the fourth group of patients didn’t receive any kind of psychiatric treat-
ment. We used psychotherapeutic interview with detailed clinical assessment using DSM-IV criteria for mental disorders, 
specially structured non-standardized questionnaire for assessment of etiological factors in development of mental disorders, 
Hamilton Anxiety Scale (HAM-A), Hamilton Depression Scale (HAM-D). The subjects fi lled the questionnaires on entry, 
one moth and two months after the beginning of research. Psychotherapeutic treatment was conducted once a week. All of 
the therapeutic approaches of liaison psychiatrist applied in the treatment of women with breast cancer are successful in 
reduction of anxiety and depression. Liaison psychiatrist’s combined approach of psychopharmacological and psycho-
therapeutic treatment of breast cancer patients with depression obtained better results than separate approach.
Key words: breast cancer, liaison psychiatry, anxiety, depression
Introduction
Received for publication July 14, 2013
378
S. Anton et al.: Effi casy of Psychiatric Treatment in Breast Cancer, Coll. Antropol. 39 (2015) 2: 377–383
Physical symptoms of anxiety implicate many organ 
systems, particularly cardiovascular and gastrointestinal 
systems. Symptom overlapping may also include treat-
ment side effects and symptoms of pain. Those symptoms 
include: palpitations, sweating, gastric pain, feeling of lack 
of air and choking, dizziness and paresthesias. Often, 
panic attacks appear after which there is a constant fear 
of their recurrence. Parasympathetic symptoms are usual 
as well, such as: abdominal discomfort, nausea, diarrhea, 
vegetative imbalance, loss of appetite and sexual interest.
Anxiety is associated with uneasy feeling, alertness, 
inhibition, irritability, inability to relax, sleeping diffi cul-
ties. Patients are overwhelmed with ruminations concern-
ing cancer, fears of physical destruction or death, and 
majority of them need help in overcoming those 
thoughts16,17. Their thoughts are catastrophic and over-
generalizing. Their view of the situation is without control 
and with the feeling of helplessness. They seem worried 
and withdrawn.
Over time, after the completion of somatic treatment, 
patients are left without everyday support of medical staff, 
they are left by themselves and they develop additional 
mental diffi culties, so that the need for psychiatric help is 
enhanced. Paradoxically, after the ending of somatic treat-
ment, level of anxiety increases considerably which is con-
nected with the loss of constant supervision over treat-
ment and daily emotional support of medical staff17,18.
Patients usually consider their mental problems as a 
normal reaction to the diagnosis of cancer, so they do not 
seek treatment19. Sometimes the doctors who treat pa-
tients do not think about their mental diffi culties and as-
sume they do not require treatment which is a huge ob-
stacle in mental wellbeing of those patients.
The patients’ basic fear is the fear of painful dying. 
Additionally, there is a fear of disability, dependence, 
change of body image and physical functioning, and fi -
nally, there’s a fear of losing important persons. Primary 
fears usually disappear after a few weeks with the help of 
support from family, friends and medical staff which 
brings hope in the treatment. Some patients detain high 
level of depression and anxiety that last for weeks and 
months. They cannot adapt and cope with the constant 
distress and they need psychiatric treatment.
Age of cancer onset, earlier emotional stability, coping 
skills, sense of control and support from the environment 
are of crucial importance for anxiety development20,21. 
Anxiety is positively correlated with helplessness, fatality 
and anxious preoccupation, and negatively correlated with 
the fi ghting spirit22,23.
Most cancer patients express anxiety as part of the 
Adjustment Disorder which appears at greater prevalence 
than is the case in chronically ill and the general popula-
tion24. Adjustment Disorder is the third most common 
reason for seeking psychiatric help (after depression and 
organic mental disorders)1. The problem is, however, that 
diagnostic criteria for those diagnoses in somatic patients 
are also not clearly set14,15,25.
There are numerous evidence of connection between 
cancer and development of depressive reactions, as well as 
of the infl uence of depression as a risk factor on the devel-
opment of cancer26,27. The range of mood disorders in can-
cer patients spans from sadness to Major Depressive Dis-
order28. Frequency of depression rises with the progression 
of malignant disease. Some research state that 55% of 
terminally ill patients suffer from depression. Depression 
is connected with poor compliance, passivity, family dy-
namics disturbances, all of which additionally infl uences 
the course of cancer treatment. It is recommended that 
evaluation of every depressed cancer patient must include 
consideration of medical, endocrine and neurological fac-
tors as well as cognitive assessment29. Patients should be 
actively listened to, allowing them to express all of their 
emotions, fears and anger in a setting which is not con-
demning, allowing them to experience feeling of con-
trol30–32.
The preferred therapeutic approach to cancer patient 
treatment is a short supportive psychotherapy based on 
the crisis intervention model33,34. This approach offers 
emotional support, provides information on how to over-
come the crisis, emphasizes personal abilities and sup-
ports earlier successful problem solving strategies. Cancer 
patients (and their family members, if needed) are in 
treatment once a week with the aid of psychopharmaco-
therapy where needed35–38. Cognitive-behavioral tech-
niques include relaxation (most commonly progressive 
muscular relaxation), distraction and cognitive repro-
gramming39–44. The communication with a cancer survivor 
who has gone through the treatment and is now considered 
cured is often of use45,46.
Purpose of research
The object of this research is to evaluate the infl uence 
of different psychiatric treatment methods on anxiety and 
depression of women with newly diagnosed breast cancer.
Subjects and Methods
Participants
The sample consisted of 120 women treated at the De-
partment of Oncology, University Hospital Center Osijek, 
and involved in a liaison psychiatric treatment.
Inclusion Criteria: female sex, age between 18–65, 
newly diagnosed breast cancer, radiotherapy as part of the 
cancer treatment, Hamilton depression scale (HAM-D) 
from ≥8 to ≤24 or values Hamilton anxiety scale (HAM-A) 
from ≥17 to ≤30, absence of severe physical ailments, no 
medical history of past or present psychotic disturbances, 
elementary school as the lowest educational level, ade-
quate conversation ability, signed patients’ informed con-
sent.
Exclusion Criteria: unacceptance of participation in 
research as defi ned in patients’ informed consent, pres-
ence of other severe physical diseases, pregnancy, breast-
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feeding, positive history of past or present psychotic dis-
order, mental retardation, major personality disorder, 
permanent personality disorders, psychoactive substance 
or alcohol abuse during the last 3 months prior to the be-
ginning of research, earlier participation in any form of 
psychotherapeutic treatment.
Procedure
Subjects were divided into four groups. Every group 
consisted of 30 subjects.
Subjects’ segregation was randomized by researcher-
psychiatrist using the random numbers table.
First group was treated by psychopharmacotherapy.
Second group was treated by psychotherapy. This 
group of patients was further divided in two subgroups:
 ● A group of subjects treated by individual, dynamic ori-
ented psychoanalytic therapy.
 ● A group of subjects treated by cognitive-behavioral psy-
chotherapy.
Third group was treated by a combination of psycho-
pharmacotherapy and psychotherapy. This group was fur-
ther divided in two subgroups:
 ● A group of subjects treated by a combination of psycho-
pharmacotherapy and dynamic oriented psychoana-
lytic therapy.
 ● A group of subjects treated by a combination of psycho-
pharmacotherapy and cognitive-behavioral psycho-
therapy.
Fourth group was consisted of a control group which 
was not under any psychiatric treatment.
Psychotherapeutic procedures were conducted once a 
week for the fi rst two months of research, and afterwards 
according to clinical presentation and subjects’ motivation 
up to a year in duration.
Apparatus
Prior to the beginning of the research, all subjects have 
signed an informed consent for the participation in re-
search.
The research included:
1. Detailed clinical examination with psychiatric inter-
view and implementation of diagnostic criteria accord-
ing to DSM-IV for mental disorders.
2. Application of specifi cally structured no-standardized 
questionnaire for detailed assessment of possible etio-
logical factors of subjects’ psychic disorder.
3. Assessment of subjects’ anxiety and depression using 
Hamilton Anxiety Scale47 and Hamilton Depression 
Scale48.
The measurements of anxiety and depression were per-
formed three times: on the fi rst day of research, one month 
and two months after the beginning of research. The re-
search lasted for three years.
Results
Demographic data
The research included middle aged women. The aver-
age age of subjects was 56.52 years (minimum 24, max-
imum 65) with standard deviation 8.628. Most of them 
had a quadrant surgery on their breast (quadrantecto-
my) 51.67 %. Most of the questioned women had com-
pleted primary school or secondary school (90%), had 
steady employment (36.17%) or they were retired (28.34 
%), but there were also students in the sample (2.5 %). 
Most subjects were from the rural area (59.17 %). Most 
of them were married (61.67 %) or widowed (27.5%) and 
had two (44.17 %) or three or more than three children 
(28.33 %).
Results showed there were no displaced persons or 
refugee’s status in most women (72.5%). Of the women 
who went through that traumatic experience, 36.4% have 
spent less than one year in refugees, and 24.2% more 
than seven years. Because of the small number of women 
who were in that category the fact is not statistically sig-
nifi cant and, therefore, it had no greater infl uence on 
development of the strongest pathology. Most of the ques-
tioned women described the intensity of their psychical 
disorders as medium (48%), 26.7% of them described 
minimal intensity of psychical disorders, 16.7% strong, 
and psychical disorders that incapacitated them in their 
life or their activity was spotted in 9.2% of the questioned 
women.
Analysis of anxiety according to HAM-A results
The difference in results in all groups is statistically 
relevant between first and second measurement 































Fig. 1. Results on HAM-A across groups and measurements.
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Statistical signifi cance of results on HAM-A across 
groups and measurements is presented in Table 1.
Distribution of results on HAM-A depending on 
anxiety intensity and across groups
The difference in results between measurements is 
statistically relevant (p<0.0000) (Figure 2). The difference 
in results between measurements is statistically relevant 
(p<0.0000) (Figure 3). The difference in results between 
measurements is statistically relevant (p<0.0000) (Figure 
4). The difference in results between measurements is not 
statistically relevant (p<0.1889) (Figure 5).
Analysis of anxiety according to HAM-D results
The difference in results in all research groups was 
statistically signifi cant between fi rst and second measure-
ment (p<0.0000) and between fi rst and third measure-
ment (p<0.0000) (Figure 6). Statistical signifi cance of 
TABLE 1






1–2 1–3 1–4 2–3 2–4
First and second 
measurement * * 0.0007 * 0.0002
First and third 































Fig. 6. Results on HAM-D across groups and measurements.
Fig. 2. HAM-A results by anxiety intensity for the fi rst group.
Fig. 4. HAM-A results by anxiety intensity for the third group.
Fig. 3. HAM-A results by anxiety intensity for the second group.
Fig. 5. HAM-A results by anxiety intensity for the fourth group.
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results on ham-d across groups and measurements is pre-
sented in Table 2.
Distribution of results on HAM-D depending on 
depression intensity across groups
The difference in results between measurements is 
statistically signifi cant (p<0.0002) (Figure 7). The differ-
ence in results between measurements is statistically sig-
nifi cant (p<0.0000) (Figure 8). The difference in results 
between measurements is statistically significant 
(p<0.0000) (Figure 9). The difference in results between 
measurements is not statistically signifi cant (p<0.0989) 
(Figure 10).
Discussion and Conclusion
Breast cancer patients today have more treatment op-
tions, but their psychological reactions to cancer diagnosis 
have remained the same. Even though the breast cancer 
is a huge stress for any woman, there is a big difference in 
psychological response among them49–52.
The subjects included in this research were in the 
course of their illness when they were still focused on the 
somatic disease and have received radiotherapy; therefore, 
the experience of the somatic illness was in the spot light. 
They still haven’t become aware of majority of their men-
tal diffi culties, neither have they been able to verbalize 
them. They have considered them as a part of the »normal« 
reaction. Anxiety is usually amplifi ed by the perception of 
radiotherapy destroying their body. Many of them keep 
checking if the disease has returned or progressed, and 
they often have the need to avoid actuating situations such 
as vicinity of the hospital53. Claustrophobic patients can-
not bare treatment in small and confi ned spaces (radio-
therapy).
At the beginning of this research, majority of patients 
in the combined treatment group (psychopharmacothera-
py + psychotherapy) (73.37%) displayed medium level of 
anxiety, while at the end of the treatment, most of them 
were in the range of mild anxiety (86.67%). In the control 
TABLE 2






1–2 1–3 1–4 2–3 2–4
First and second 
measurement * * 0.0002 * 0.0000
First and third 
measurement * 0.0226 0.0000 0.0254 0.0000
*p>0.05
Fig. 7. HAM-D results by depression intensity for the fi rst group.
Fig. 9. HAM-D results by depression intensity for the third 
group.
Fig. 8. HAM-D results by depression intensity for the second 
group.
Fig. 10. HAM-D results by depression intensity for the fourth 
group.
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group the level of anxiety was rising (over 30%), but, nev-
er the less, some women expressed only mild symptoms of 
anxiety.
Analyzing the levels of anxiety according to HAM-A, 
the effi cacy of all psychiatric therapeutic methods in treat-
ment of women with breast cancer in comparison with the 
control group is evident. In the control group the anxiety 
level was increasing, while the intervention groups had a 
decrease in anxiety level over time. Combination of treat-
ment, however, showed the best benefi t.
Analyzing the levels of depression according to HAM-D 
the effi cacy of all psychiatric therapeutic methods in treat-
ment of women with breast cancer in comparison with the 
control group is evident. In the control group the depres-
sion level was increasing, while the intervention groups 
had a decrease in depression level over time. Again, the 
combination of psychopharmacological and psychothera-
peutic treatment demonstrated the best benefi t.
In the group of subjects treated with the combination 
of psychotherapy and psychopharmacotherapy, most wom-
en (50%) belonged to a subgroup of moderate depression, 
followed by severe (30%) and mild (20%) depression. After 
only a month of treatment, the decrease of depression was 
evident. At the end of the research, 36.67% of women 
didn’t show symptoms of depression, 40% had mild depres-
sion, 20% moderate and 3.33% of patients had severe de-
pression.
According to this research, psychopharmacological 
treatment demonstrated positive effect. Never the less, in 
comparison to combined additional psychotherapeutic 
treatment, the effect was smaller. Similarly, the psycho-
therapeutic methods showed effi ciency, but to a lesser de-
gree in comparison with combined additional psychophar-
macologic treatment.
In the control group, which received no psychiatric 
treatment, at the beginning of research 46.67% of women 
showed moderate depression, 36.67% had mild depression, 
13.33% had severe depression and only 3.33% of women 
showed no signs of depression. Over time, by the end of 
research 46% of women expressed severe depression, 30% 
moderate, 10% mild, and 13% of women were without 
symptoms of depression. There is an evident and worrying 
increase of severe forms of depressive responses which 
clearly require psychiatric treatment. But also, there are 
women who do not develop depression, and even show 
spontaneous remission of depressive symptoms over time!
Majority of women treated with psychopharmacother-
apy received a combination of antidepressants and anxio-
lytics (71.67%). Anxiolytics as a monotherapy were admin-
istered in only 28.33% of cases. 
Psychopharmacotherapeutics significantly reduce 
symptoms of anxiety and depression and as such can be of 
much use to patients. Therapeutic effects are even bigger 
if psychopharmacotherapy is understood as a tool in 
achieving stability of mental condition in which the pa-
tients will be more capable to accept additional psycho-
therapeutic treatment and assume more active attitude in 
treatment of their mental disorders. Considering coping 
mechanisms some of the subjects used in dealing with 
diffi culties, a lot of them demonstrated the »fi ghting spir-
it« and were very active in combat with the disease using 
their own strengths. This study has demonstrated that 
additional psychotherapeutic treatment achieved even bet-
ter results.
As it is often emphasized, psychiatric help cannot be 
provided to everybody (neither it is required by all, as the 
results of this study demonstrate), but it is important to 
diagnose women who do require treatment and offer it to 
them54,55. Test ratings emphasize the need for screening 
so that the therapist can direct himself on women with 
severe mental diffi culties which can be effectively treated 
as has been demonstrated by this research. Constant su-
pervision and evaluation of patients’ condition is required 
throughout the course of illness because there are a lot of 
crisis states which can lead to amplifi cation of anxiety, 
depression and other mental disorders.
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USPJEŠNOST RAZLIČITIH TERAPIJSKIH PRISTUPA KONZULTATIVNO-SURADNOG PSIHIJATRA 
U LIJEČENJU ŽENA S KARCINOMOM DOJKE
S A Ž E T A K
Obolijevanje od karcinoma dojke predstavlja traumatski događaj koji može dovesti do razvoja raznih psihičkih 
poremećaja i utjecati na sve aspekte života oboljele žene. Anksiozni i depresivni poremećaji kod tjelesno bolesnih još 
uvijek nemaju jasno defi nirane kriterije što značajno otežava dijagnosticiranje i liječenje, a i različiti psihijatrijski tera-
pijski pristupi imaju različite učinke. Cilj istraživanja bio je procijeniti utjecaj zasebne primjene i kombinacije psiho-
terapijskog pristupa različite vrste (psihodinamski i kognitivno-bihevioralni) i psihofarmakoterapije na smanjenje 
anksioznosti i depresivnosti u bolesnica s karcinomom dojke. Uzorak je činilo 120 ispitanica podijeljenih u četiri skupine. 
Prva skupina ispitanica bila je liječena psihofarmakoterapijom, druga psihoterapijski, treća kombinirano (psihofarma-
koterapijom i psihoterapijom), a četvrta nije bila podvrgnuta nikakvom psihijatrijskom terapijskom postupku. Korišteni 
su psihoterapijski intervju s detaljnim kliničkim pregledom uz primjenu DSM-IV kriterija za psihičke poremećaje, 
posebno strukturirani nestandardizirani upitnik za procjenu etioloških čimbenika u nastanku psihičkog poremećaja, 
Hamiltonova ljestvica za procjenu anksioznosti (HAM-A), Hamiltonova ljestvica za procjenu depresivnosti (HAM-D). 
Ispitanice su ispunjavale ljestvice nultog dana, nakon mjesec dana te dva mjeseca od početka istraživanja. Psihoterapi-
jski postupci bili su provođeni jednom tjedno. Svi primijenjeni terapijski postupci konzultativno-suradnog psihijatra u 
liječenju žena s karcinomom dojke uspješni su u smanjenju anksioznosti i depresivnosti ispitivanih žena. Kombinacijom 
psihofarmakološkog i psihoterapijskog pristupa konzultativno-suradnog psihijatra postižu se bolji rezultati, nego zaseb-
nom primjenom svakog od njih.
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